New oral paclitaxel trial offers hope for Hard-to-Treat GIST
NCT ID NCT06326346
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests an oral form of paclitaxel (Liporaxel) in 28 adults with advanced gastrointestinal stromal tumors (GIST) that no longer respond to three standard drugs: imatinib, sunitinib, and regorafenib. The study focuses on patients whose tumors have low levels of a protein called P-glycoprotein, which may make the drug more effective. Participants take Liporaxel twice daily on specific days each month, and researchers will track how well it controls tumor growth over 16 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- oral paclitaxel (Liporaxel)
- What this could lead to
- If it works, this could offer a new oral treatment option for GIST patients who have run out of standard therapies.
- What could go wrong
- This is a small early-phase trial with only 28 participants, so results may not apply broadly. The drug may not control tumor growth or could cause side effects like nerve damage or low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center, University of Ulsan College of Medicine
RECRUITINGSeoul, Songpagu, 138-736, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Brain-Cancer drug take on a stubborn stomach tumor?
- Study aims to pinpoint ideal imatinib dose for GIST patients
- New hope for stubborn GIST: experimental drug DCC-2618 enters safety testing
- New drug cocktail targets tough stomach cancer in Last-Resort patients
- New hope for rare stomach cancer: chemo drug shows promise in early trial
- Chemotherapy drug paclitaxel tested for Hard-to-Treat GIST